^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CDDD11-8

i
Other names: CDDD11-8
Company:
University of South Australia
Drug class:
FLT3 inhibitor, CDK9 inhibitor
Related drugs:
12ms
Selective inhibition of CDK9 in triple negative breast cancer. (PubMed, Oncogene)
Orally administered CDDD11-8 also inhibited growth of mammary intraductal TNBC xenograft tumours with no overt toxicity in vivo (mice) or ex vivo (human breast tissues). In conclusion, our studies indicate that CDK9 is a viable therapeutic target in TNBC and that CDDD11-8, a novel selective CDK9 inhibitor, has efficacy in TNBC without apparent toxicity to normal tissues.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDK9 (Cyclin Dependent Kinase 9)
|
MYC amplification
|
CDDD11-8